Clinical trials: Asthma Patients
Rhinitis, Conjunctivitis
Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients
The aim of this study is to test the pharmacodynamic equivalence with respect to IgE-blocking factor and to compare the tolerability of two different updosing schedules with ALK-Flex SQ
- Conditions
- Rhinitis, Conjunctivitis, Asthma
- Trial name
- NCT00857779
- Testing
- subcutaneous immunotherapy
- Where
- Germany
- Volunteers
- 473 people
- Sponsor
- ALK-Abelló A/S
Asthma
Triple in Asthma Dose Finding
Primary objective The primary objective was to evaluate the efficacy of a free combination of CHF 5259 at 3 dose levels plus Foster® 100/6 μg in a pMDI by comparison with Foster® 100/6 μg in terms of forced expiratory volume in…
- Trial name
- Triskel (NCT02127866)
- Testing
- CHF 5259 plus Foster 100/6 µg, Foster 100/6 µg (four puffs BID)
- Where
- 44 sites in Bulgaria, Germany and 4 more
- Volunteers
- 211 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma
The purpose of this trial is to characterize the bronchodilator effects and safety of 25 ug and 50 ug o.d. NVA237 (glycopyrronium bromide) doses compared to placebo in asthma patients
- Trial name
- NCT03137784
- Testing
- NVA237 (glycopyrronium bromide)
- Where
- 21 sites in United States, Belgium and 4 more
- Volunteers
- 148 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States
A retrospective database pre-post cohort study, identifying asthmatic patients, aged 6- 11, with omalizumab use over 24 months
- Trial name
- NCT05157087
- Testing
- Omalizumab
- Where
- United States
- Volunteers
- 16,246 people
- Sponsor
- Novartis Pharmaceuticals
Seasonal Allergic Rhinoconjunctivitis, Asthma
Efficacy of Co-administration of Bilastine and Montelukast in Patients With SARC and Asthma
The purpose of this study is to compare concomitant administration of Montelukast and Bilastine to Montelukast and Bilastine monotherapies in patients with SARC and asthma
- Trial name
- SKY (NCT02761252)
- Testing
- Bilastine 20mg, Montelukast 10mg
- Where
- 32 sites in Croatia, Czechia and 6 more
- Volunteers
- 454 people
- Sponsor
- Menarini International Operations Luxembourg SA
Asthma
Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma
The primary objective of this study is to determine the optimum dose(s) of BI 1744 CL inhalation solution delivered by the Respimat® inhaler for four weeks in patients with asthma.
- Trial name
- NCT00467740
- Testing
- BI 1744 CL
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 296 people
- Sponsor
- Boehringer Ingelheim
Allergic Rhinoconjunctivitis
Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense
Based on EMA (European Medicines Agency) new guidelines on the clinical development of products for immunotherapy for the treatment of allergic diseases the aim of this study is to establish a dose-response relationship for…
- Trial name
- NCT01567306
- Testing
- Allergovac Depot
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 151 people
- Sponsor
- Roxall Medicina España S.A
Asthma
Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients
The primary objective of this trial is to investigate the safety and tolerability of BI 1060469 in healthy male and female subjects after oral administration of repeated rising doses of 3 mg, 10 mg, 25 mg, 75 mg, 150 mg and 250…
- Trial name
- NCT02126865
- Testing
- BI 1060469 Healthy, BI 1060469 asthmatics
- Where
- Germany
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Asthma
Evaluation of Tiotropium 2.5 and 5 mcg Once Daily Delivered Via the Respimat® Inhaler Compared to Placebo and Salmeterol HydroFluoroAlkane (HFA) Metered Dose Inhaler (MDI) (50 mcg Twice Daily) in Patient With Moderate Persistent Asthma I
The aim of this trial is to evaluate the efficacy and safety of 2.5 and 5 mcg tiotropium over a 24-week treatment period as compared to placebo and salmeterol (50 mcg twice daily).
- Trial name
- NCT01172808
- Testing
- tiotropium Respimat® low dose, tiotropium Respimat® high dose, 50 mcg salmeterol HFA MDI
- Where
- 114 sites in United States, Brazil and 9 more
- Volunteers
- 1,071 people
- Sponsor
- Boehringer Ingelheim
Asthma, Allergic
Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.
The main objective of this study is to evaluate, in real life, the efficacy of prolonged use (6 months) of Puressentiel Air Purifying Spray with 41 essential oils on the control of allergy-induced asthma in the homes of patients…
- Trial name
- PSIndAC (NCT05352126)
- Testing
- Biocide
- Volunteers
- 80 people
- Sponsor
- Puressentiel
Asthma
Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.
The main objective of this study is to evaluate the efficacy and safety of the Armstrong's Epinephrine HFA-MDI (E004) formulation, in comparison to the Placebo (Placebo-HFA) and an Active Control (Epinephrine CFC-MDI), and to…
- Trial name
- NCT01025648
- Testing
- E004 (epinephrine inhalation aerosol), 90 mcg/actuation, E004 (epinephrine inhalation aerosol), 125 mcg, E004 (epinephrine inhalation aerosol), 220 mcg
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler
The aim of the study is to demonstrate the non-inferiority in terms of acute bronchodilator effect between a single dose of CHF 1535 NEXThaler 200/6 µg and a single dose of CHF 1535 NEXThaler 100/6 µg at two dose levels in…
- Trial name
- NCT02148120
- Testing
- Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg, Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg
- Where
- 3 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Comparative Study of the Efficacy of Biologics vs Usual Treatment on OCS Reduction for Severe Asthma Patients Using Health Insurance Claim Database
This study is a retrospective cohort study of patients diagnosed with asthma based on the data extracted from the MDV database. The study period is from 1st Jun 2016 to 29th February 2020 .
- Trial name
- HAYATE (NCT05136547)
- Where
- Japan
- Volunteers
- 2,927 people
- Sponsor
- AstraZeneca
Asthma
As Needed Beclomethasone/Salbutamol Combination in Single Inhaler for Mild Persistent Asthma
The aim of this study is to reveal that inhaled corticosteroid therapy combined with a short-acting beta2- agonist given on a symptom driven basis is as effective as traditional asthma therapy.
- Trial name
- NCT00382889
- Testing
- beclomethasone/salbutamol combination, beclomethasone, salbutamol
- Where
- 25 sites in Austria, Italy and 2 more
- Volunteers
- 480 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
Effect of a Pharmaceutical Intervention on the Level of Control of the Asthmatic Patient
Measurement of disease control, treatment adherence and patient knowledge of his/her medication in patients that are receiving a pharmaceutical intervention compared with those patients who receive regular pharmaceutical care.
- Trial name
- NCT01085474
- Testing
- 1, 2
- Where
- 2 sites in Spain
- Volunteers
- 384 people
- Sponsor
- AstraZeneca
Moderate-to-severe Allergic Asthma
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma.
- Trial name
- EDURO (NCT04195958)
- Testing
- Omalizumab
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Asthma
Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)
Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. In this study the effect of ciclesonide on airway hyperresponsiveness (AHR), exhaled nitric oxide (NO), and induced sputum inflammatory biomarkers will be…
- Trial name
- NCT00546520
- Testing
- Ciclesonide
- Where
- United Kingdom
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Asthma
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MTPS9579A in Patients With Asthma Requiring Inhaled Corticosteroids and a Second Controller
This is a Phase IIa, randomized, placebo-controlled, double-blind, multicenter, two-arm study to evaluate the efficacy, safety, and pharmacokinetics of MTPS9579A as an add-on therapy in patients with uncontrolled moderate to…
- Trial name
- NCT04092582
- Testing
- MTPS9579A
- Where
- 27 sites in United States, Argentina and 3 more
- Volunteers
- 135 people
- Sponsor
- Genentech, Inc.